X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (922) 922
Journal Article (612) 612
Publication (45) 45
Conference Proceeding (17) 17
Magazine Article (3) 3
Book Chapter (2) 2
Book / eBook (1) 1
Data Set (1) 1
Journal / eJournal (1) 1
Technical Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (446) 446
metallurgy (442) 442
performing operations (393) 393
transporting (393) 393
adhesives (295) 295
dyes (295) 295
miscellaneous applications of materials (295) 295
miscellaneous compositions (295) 295
natural resins (295) 295
paints (295) 295
polishes (295) 295
chemical paint or ink removers (291) 291
coating compositions, e.g. paints, varnishes orlacquers (291) 291
correcting fluids (291) 291
filling pastes (291) 291
inks (291) 291
pastes or solids for colouring or printing (291) 291
use of materials therefor (291) 291
woodstains (291) 291
physics (258) 258
lining machines (250) 250
printing (250) 250
stamps (250) 250
typewriters (250) 250
correction of typographical errors (236) 236
i.e. mechanisms printing otherwise than from a forme (236) 236
selective printing mechanisms (236) 236
colour printing (199) 199
printing, duplicating, marking, or copying processes (199) 199
humans (177) 177
electricity (171) 171
index medicus (134) 134
optics (111) 111
female (108) 108
male (108) 108
basic electric elements (106) 106
lakes (103) 103
middle aged (103) 103
mordants (103) 103
organic dyes or closely-related compounds for producing dyes (103) 103
aged (92) 92
hematology (92) 92
adult (89) 89
electric solid state devices not otherwise provided for (87) 87
semiconductor devices (87) 87
blasting (80) 80
heating (80) 80
lighting (80) 80
mechanical engineering (80) 80
weapons (80) 80
oncology (75) 75
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (68) 68
frequency-changing (68) 68
non-linear optics (68) 68
optical analogue/digital converters (68) 68
optical logic elements (68) 68
paper (68) 68
techniques or procedures for the operation thereof (68) 68
measuring (67) 67
testing (67) 67
textiles (66) 66
alloys (64) 64
ferrous or non-ferrous alloys (62) 62
treatment of alloys or non-ferrous metals (62) 62
lymphomas (61) 61
chemotherapy (59) 59
cancer (55) 55
flexible materials not otherwise provided for (55) 55
laundering (55) 55
treatment of textiles or the like (55) 55
optical elements, systems, or apparatus (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (52) 52
dyeing leather, furs, or solid macromolecular substances inany form (52) 52
dyeing or printing textiles (52) 52
advertising (51) 51
cryptography (51) 51
display (51) 51
education (51) 51
seals (51) 51
investigating or analysing materials by determining theirchemical or physical properties (50) 50
treatment outcome (48) 48
aged, 80 and over (46) 46
cinematography (46) 46
electrography (46) 46
fixed constructions (46) 46
holography (46) 46
photography (46) 46
microbiology (45) 45
young adult (44) 44
general devices for heat treatment of ferrous or non-ferrousmetals or alloys (42) 42
making metal malleable by decarburisation, tempering or othertreatments (42) 42
metallurgy of iron (42) 42
modifying the physical structure of ferrous metals (42) 42
prognosis (42) 42
rituximab (42) 42
displaying (41) 41
human necessities (41) 41
labels or name-plates (41) 41
layered products (41) 41
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (41) 41
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1499) 1499
Japanese (125) 125
German (112) 112
French (104) 104
Chinese (44) 44
Korean (6) 6
Portuguese (4) 4
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Yamagami, Keitaro and Kurogi, Ryota and Kurogi, Ai and Nishimura, Hiroyuki and Nishimura, Shinjitsu and Nishimura, Yasuaki and Nishimura, Kunihiro and Nishimura, Ataru and Onozuka, Daisuke and Ren, Nice and Kada, Akiko and Arimura, Koichi and Ido, Keisuke and Mizoguchi, Masahiro and Sakamoto, Seisaburo and Sakamoto, Tetsuya and Kayama, Takamasa and Suzuki, Nozomi and Suzuki, Michiyasu and Suzuki, Sachio and Suzuki, Hidenori and Suzuki, Ichiro and Suzuki, Susumu and Arai, Yoshinori and Arai, Hajime and Arai, Motohiro and Hagihara, Akihito and Iihara, Koji and Takigami, Masayoshi and Kamiyama, Kenji and Houkin, Kiyohiro and Nishi, Shougo and Yoshimoto, Tetsuyuki and Yoshimoto, Junpei and Kaneko, Sadao and Oka, Hirofumi and Oka, Koji and Ooyama, Hiroshi and Kamada, Kyousuke and Makino, Kenichi and Tokumitsu, Naoki and Sako, Kazuhiro and Izumi, Naoto and Nitta, Hisashi and Nitta, Kazumi and Ootaki, Masahumi and Isobe, Masanori and Nishiya, Mikio and Yamazaki, Takaaki and Mabuchi, Syouji and Mabuchi, Eiichiro and Ogasawara, Kuniaki and Kubo, Naohiko and Shimizu, Yukihiko and Saito, Hitoshi and Saito, Keiichi and Yamanome, Tatumi and Yoshino, Kimihiro and Yoshino, Atsuo and Fujitsuka, Mitsuyuki and Takami, Masaaki and Ohtaka, Hirotoshi and Hirano, Teruyuki and Shiokawa, Yosiaki and Okada, Takaharu and Kohno, Michihiro and Haraoka, Jou and Kawamura, Noriyoshi and Kawamura, Tadao and Isoshima, Akira and Yasue, Masaharu and Takayoshi Kobayashi, Mitsuhiko Hokari and Kawai, Kensuke and Maehara, Taketoshi and Noguchi, Makoto and Hoshino, Haruhiko and Hiyama, Hirofumi and Yoshida, Kensaku and Yoshida, Kazunari and Utsugi, Osamu and Takeda, Yasuaki and Takeda, Yuu and Tamaki, Kouichi and Karasudani, Hirohide and Urabe, Takao and Kobayashi, Nozomu and Kobayashi, Shiro and Nakamura, Yusaku and Nakamura, Kazuhito and Nakamura, Michio and Nakamura, Yoshinari and Koguchi, Yorio and Ono, Junichi and Suda, Sumio and Hadeishi, Hiromu and Fukutake, Toshio and Wakui, Kenji and Tanno, Hirokazu and Ishige, Naoki and Ohasi, Takashi and ... and J-ASPECT Study Collaborators
World Neurosurgery, ISSN 1878-8750, 10/2019, Volume 130, pp. e26 - e46
The epidemiology of patients with traumatic brain injury (TBI) has changed dramatically over recent decades as a result of rapid advances in aging societies.... 
Aging | Hospital mortality | Prognosis | Traumatic brain injury | Subdural hematoma
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S168 - S169
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1019 - 1026
Summary Background Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide,... 
Hematology, Oncology and Palliative Medicine | THERAPY | OLDER PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | CLASSIFICATION | RANDOMIZED CONTROLLED-TRIAL | TARGETING BTK | ELDERLY-PATIENTS | CHEMOTHERAPY | Doxorubicin - therapeutic use | Pyrazoles - therapeutic use | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Non-Randomized Controlled Trials as Topic | Aged, 80 and over | Adult | Female | Lymphoma, Non-Hodgkin - drug therapy | Pyrazoles - adverse effects | Severity of Illness Index | Antigens, CD20 - immunology | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Administration, Oral | Rituximab | Survival Rate | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - diagnosis | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Antigens, CD20 - drug effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Care and treatment | Anthracyclines | Cyclophosphamide | Prednisone | Corticosteroids | Tumors | Index Medicus
Journal Article
Cancer treatment and research, ISSN 0927-3042, 2019, Volume 176, pp. 163 - 184
NK-cell malignancies are rare aggressive diseases associated with poor clinical outcome. There is a significant geographic variation in their incidence. At... 
NK-cell lymphoma | Treatment | Review | Stem cell transplant | Concurrent chemoradiotherapy | L-asparaginase
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. 1311 - 1318
Journal Article
SAE technical paper series, Volume 2012-01-1017.
Reflecting on the world's trend on saving crude oil consumption and to create an economical fuel efficient vehicle for the increasing world population, a new... 
Power and Propulsion | Variable valve timing | Downsizing | Product development | Hybrid electric vehicles
eJournal
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 48 - 56
Journal Article
Angewandte Chemie International Edition, ISSN 1433-7851, 08/2018, Volume 57, Issue 32, pp. 10278 - 10282
We have discovered that the racemization of configurationally stable, axially chiral 2,2′‐dihydroxy‐1,1′‐biaryls proceeds with a catalytic amount of a... 
ruthenium | biaryl compounds | racemization | dynamic kinetic resolution | lipase | Lipase | Synthesis | Organic compounds | Racemization | Catalysis | Asymmetric synthesis | Diols
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 622 - 631
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 389 - 400
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 13, pp. 1222 - 1228
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 331 - 344
BACKGROUND Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. METHODS We... 
TRIAL | ABVD | MEDICINE, GENERAL & INTERNAL | POSITRON-EMISSION-TOMOGRAPHY | RESPONSE CRITERIA | DISEASE | PROGNOSTIC SCORE | OPEN-LABEL | TOXICITY | INTERGROUP | COOPERATIVE-ONCOLOGY-GROUP | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Immunoconjugates - administration & dosage | Young Adult | Aged, 80 and over | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Dacarbazine - administration & dosage | Immunologic Factors - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Immunologic Factors - adverse effects | Neoplasm Staging | Vinblastine | Hematology | Toxicity | Prophylaxis | Clinical trials | Oncology | Peripheral neuropathy | Cancer therapies | Doxorubicin | Survival | Lymphoma | Medicine | Dacarbazine | Chemotherapy | Bleomycin | CD30 antigen | Granulocyte colony-stimulating factor | Death | Colony-stimulating factor | Lymphomas | Leukocytes (granulocytic) | Drug dosages | Hodgkin's disease | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article